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DESCRIPTION of CASE
A 
52-year-old female presented to an otolaryngologist 
with a hoarse voice. An endocrine opinion was sought 
to exclude an underlying endocrinopathy. She had 
been investigated three years previously by a neurologist 
for right-sided facial pain. A magnetic resonance imaging 
(MRI) scan had shown a small “cyst” in the pituitary gland. 
She had been reassured that this was a coincidental ﬁ  nding. 
The patient did not volunteer any speciﬁ  c symptoms and had 
no complaints other than a hoarse voice. Her appearance is 
shown in Figure 1.
How Should a Patient with Suspected Pituitary Disease 
Be Worked Up?
The above scenario is increasingly common as a result of 
the advent of powerful imaging techniques such as MRI 
and computerised tomography scanning, which identify 
“coincidental” pituitary abnormalities in a signiﬁ  cant minority 
of the adult population. Nonetheless, when such lesions are 
identiﬁ  ed they warrant further characterisation.
The clinician confronted with such a case should ask the 
following questions:
•  Is there evidence of over secretion of pituitary hormone(s)?
•  Is there evidence of deﬁ  ciency of pituitary hormones?
•  Is there evidence of pressure on structures surrounding the 
pituitary fossa?
The commonest cause of excess pituitary hormone 
secretion is a prolactinoma. It usually presents with 
galactorrhoea, oligo- or amenorrhoea, and hirsutism in 
premenopausal women and with hypogonadism in men. 
Cushing disease and acromegaly are less common and 
gonadotrophin-secreting adenomas and thyrotrophinomas 
are rare. Mild hyperprolactinaemia is commonly found in 
association with large pituitary tumours and is usually due 
to distortion of the pituitary stalk. This “disconnection” 
syndrome must be distinguished from a true prolactin-
producing adenoma, as the treatment of the latter (with 
dopamine agonist drugs) is radically different from that of 
other types of pituitary adenomas.
Hypopituitarism can present with features of 
hypogonadism (amenorrhoea, loss of body hair, loss of libido 
and impotence), hypothyroidism, and hypoadrenalism. The 
latter, in addition to symptoms of hypocortisolism (tiredness, 
dizziness, fatigue) may also be associated with loss of ability to 
tan and generalised hypopigmentation.
Expansion of a pituitary mass superiorly can compress the 
optic chiasm, thus giving rise to bitemporal hemianopia. 
Lateral extension can compress cranial nerve III, IV, or VI. 
Occasionally pituitary tumours can bleed or infarct to cause 
pituitary apoplexy (sudden headache, photophobia, cranial 
nerve palsies, and collapse due to hypoadrenalism and in 
some cases hypoglycaemia). Investigations include pituitary 
function tests, formal visual ﬁ  eld assessment, and in some 
cases further more detailed imaging.
Despite the absence of spontaneous symptoms, the patient 
admitted to increasing hand and shoe size when speciﬁ  cally 
asked, associated with a hoarse voice of three years duration. 
She had also suffered from frontal headaches as well as 
tingling of the right index ﬁ  nger. Previously, she had surgery 
for temporomandibular joint dysfunction. 
On closer inspection, there was a suggestion of some 
broadening of the nose and prominence of the lips, rather 
large hands, and increased skin thickness (Figure 1). Visual 
ﬁ  elds were normal and Tinel’s sign was positive. Blood 
pressure (BP) was 160/96 mm Hg. Blood tests showed normal 
urea, creatinine and electrolytes, fasting glucose of 6.6 mmol/
l (normal range, <5.6 mmol/l), prolactin 330 imu/l (normal 
A 52-Year-Old Female with a Hoarse Voice 
and Tingling in the Hand
Salman Razvi*, Petros Perros
Funding: The authors received no speciﬁ  c funding for this article. 
Competing Interests: The authors have declared that no competing interests exist.
Citation: Razvi S, Perros P (2007) A 52-year-old female with a hoarse voice and 
tingling in the hand. PLoS Med 4(3): e29. doi:10.1371/journal.pmed.0040029
Copyright: © 2007 Razvi and Perros. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited. 
Abbreviations: CTS, carpal tunnel syndrome; GH, growth hormone; IGF 1, 
insulin-like growth factor 1; MRI, magnetic resonance imaging; OGTT, oral glucose 
tolerance test; TSH, thyroid stimulating hormone
Salman Razvi is with the Endocrine Unit, Royal Victoria Inﬁ  rmary, Newcastle upon 
Tyne, United Kingdom. Petros Perros is with the Endocrine Unit, Freeman Hospital, 
Newcastle upon Tyne, United Kingdom.
* To whom correspondence should be addressed. E-mail: salmanrazvi@hotmail.
com
The Learning Forum discusses an important clinical problem of relevance 
to a general medical audience.
doi:10.1371/journal.pmed.0040029.g001
Figure 1. Appearance of the Patient
The patient’s facial appearance shows some broadening of the nose and 
supra orbital ridges (left). At right, the patient’s large hands are shown.PLoS Medicine  |  www.plosmedicine.org 0444
<550 imu/l), and thyroid stimulating hormone (TSH) of 1.4 
mIU/l (normal 0.3–4.7 mIU/l) with free T4 of 16 pmol/l 
(normal 11–23 pmol/l). 
What Is the Reason for the Tingling of the Right 
Index Finger?
The sensory disturbance in the distribution of the median 
nerve is typical of right carpal tunnel syndrome (CTS). CTS 
typically presents as pain in the medial three ﬁ  ngers radiating 
into the arm, worsening during the night.
Thickening of tendons or synovitis in the carpal tunnel 
area causes CTS. The history, in this patient, is typical of 
CTS and is characterised by pain, tingling, and numbness in 
the median nerve distribution. This patient does not have 
hypothyroidism (normal thyroid hormone and serum TSH 
levels) or diabetes mellitus (although she has impaired fasting 
glycaemia), was not pregnant or obese, and did not have a 
history or clinical manifestations of rheumatoid arthritis. 
The cause could be idiopathic, but the other features in the 
history and examination point towards endocrinopathy as 
being the underlying aetiology. The diagnosis of CTS can be 
conﬁ  rmed by an electromyogram.
Is the Combination of High Blood Pressure and High 
Fasting Glucose Levels Common?
Hypertension associated with problems with glucose 
metabolism is a common feature usually seen in people with 
the metabolic syndrome. Less commonly, it can be seen in 
endocrine diseases like Cushing syndrome and acromegaly. 
The reason for hypertension and hyperglycaemia in Cushing 
syndrome is due to the excess glucocorticoid levels whereas 
in acromegaly, it is due partly to the direct action of excess 
growth hormone (GH) on sodium retention and increased 
insulin resistance, respectively [1]. 
What Is the Next Step?
The symptoms of increasing soft tissue size, CTS, hypertension, 
hyperglycaemia, and temporomandibular joint dysfunction 
make acromegaly a possible diagnosis (Box 1). The 
duration of symptoms as well as the previous surgery for 
temporomandibular joint dysfunction suggests that the disease 
has been active for at least three years [2]. The usual (in 
98% of cases) cause of acromegaly is a GH-secreting pituitary 
adenoma, usually a macro-adenoma (>1 cm). Other rare causes 
are pituitary carcinoma or GH-releasing hormone tumours.
Baseline GH levels are of limited value in diagnosing 
acromegaly since GH is normally secreted episodically, 
and high levels can also be seen in pregnancy, puberty, in 
response to pain, stress, malnutrition, and after a prolonged 
fast. The diagnosis can be conﬁ  rmed by measuring GH levels 
in response to an oral glucose tolerance test (OGTT) (Box 
2 outlines the protocol for OGTT to diagnose acromegaly). 
Insulin-like growth factor 1 (IGF 1) is a protein modulated by 
GH and produced in many body tissues, primarily in the liver. 
Serum levels of IGF 1 are fairly stable throughout the day and 
correlate closely with mean GH serum concentration.
Symptoms due to direct effect of the tumour
• Headache
• Visual  impairment
• Hypopituitarism
• Hyperprolactinaemia
Symptoms due to GH excess
•  Soft tissue enlargement
• Headache
• Increased  skin  tags
• Increased  sweating
• Acanthosis  nigricans
Cardiovascular features
• Hypertension
• Biventricular  hypertrophy
•  Diastolic dysfunction at rest and systolic dysfunction on effort
• Endothelial  dysfunction
Metabolic and other endocrine features
• Impaired  fasting  glycaemia
• Impaired  glucose  tolerance
•  Type 2 diabetes mellitus
• Insulin  resistance
• Dyslipidaemia
• Multinodular  goitre
• Hypercalciuria
• Hyperparathyroidism
Musculoskeletal features
• Joint  stiffness
• Arthropathy  and  osteoarthritis
•  Carpal tunnel syndrome
• Osteopenia
Respiratory disease
•  Upper airway obstruction and snoring
• Macroglossia
• Obstructive  sleep  apnoea
•  Thickened vocal chords and hoarse voice
Neoplastic disease
•  Colorectal polyps and cancer
•  Probable breast, prostate, and thyroid cancer
Box 1. Symptoms and Signs of Acromegaly 
Table 1. Oral Glucose Tolerance Test with Growth Hormone 
Results
Time (minutes)    Glucose (mmol/l) GH (mu/l)
0 6.6 56.3
30 10.7 34
60 11.4 22
90 9.3 20
120 8.7 17.6
doi:10.1371/journal.pmed.0040029.t001
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Further investigation and management of patients 
with suspected pituitary disease should be undertaken in 
specialised endocrine centres, to which such patients should 
be referred.
The patient’s random GH level was 55 mu/l (0–20) along 
with an elevated IGF 1 level of 78 nmol/l (age-matched 
normal range being 12–44). She then proceeded on to an 
OGTT with glucose and GH level measurements; the results 
are outlined in Table 1.
The OGTT conﬁ  rms failure of GH to suppress to levels 
below 2 mu/l (<1 mcg/l) as well as impaired fasting 
glycaemia and impaired glucose tolerance. Other tests of 
anterior pituitary function (prolactin, thyroid function tests, 
luteinising hormone, and follicle-stimulating hormone) as 
well as dynamic testing of adrenal reserve in response to 
synthetic ACTH (short synacthen test) were normal. MRI 
studies of the pituitary gland revealed a pituitary micro-
adenoma (Figure 2). 
Should Imaging Precede the Biochemical 
Investigations?
This patient’s case highlights the dilemma clinicians are 
facing today as a result of the increasing use, availability, 
and precision of imaging techniques. She had a MRI scan 
previously that detected a pituitary tumour. Pituitary tumours 
that are detected coincidentally (so called “incidentalomas”) 
are not uncommon with reports of prevalence of up to 
10% in adults. Given the limitations of diagnostic testing, 
biochemical screening requires sufﬁ  ciently high pre-test 
probability to make it effective. Apart from the cost factor, 
an imaging-ﬁ  rst principle in any ﬁ  eld in medicine that 
relies on biochemical proof of disease leads to a cascade 
of tests and pursuit of false-positive results. Therefore, 
appropriate clinical evaluation should precede biochemical 
investigations, which then may need to be conﬁ  rmed by 
imaging techniques [3].
Should This Patient Be Treated?
The pathologic effects of increased GH levels are progressive 
and are associated with increased morbidity and mortality. 
People with acromegaly have a 2- to 4-fold increase in 
mortality rate, mostly due to cardiovascular disease [4]. 
Many of the soft tissue overgrowth features as well as the 
increased cardiovascular risk can be reversed, at least partly 
for soft tissue and completely for cardiovascular disease, 
by appropriate therapy [5]. Appropriate therapy may also 
reduce or even prevent mass effects caused by tumour growth 
in the pituitary area. It is therefore important that diagnosis 
and treatment are instituted quite promptly.
What Treatment Modalities Are Available?
The underlying treatment strategy of acromegaly is to 
remove the pituitary tumour (especially macro-adenomas 
causing mass effects), normalise GH and IGF 1 levels whilst 
preserving normal residual pituitary function, and relieve 
symptoms. Medical, surgical, and radiotherapeutic means or, 
more commonly, some combination of the three can be used 
to try and achieve this. Currently ﬁ  ve different modalities 
of treatment are available, although surgery remains the 
treatment of choice. Table 2 outlines the advantages and 
limitations of each modality. 
In this patient, it was decided that it would be prudent to 
try and regress some of the soft tissue changes of acromegaly 
to minimise the risks of intubation during anaesthesia 
(although this approach is empirical and not widely 
practised). This was achieved by a somatostatin receptor 
analogue therapy, given every month. This reduced GH levels 
to 35 mu/l and IGF 1 levels to 56 nmol/l. 
After four monthly injections of long-acting somatostatin 
receptor analogue therapy, the patient went on to have 
an endoscopic pituitary adenomectomy. Histology of the 
resected adenoma revealed a GH cell pituitary adenoma. 
How Should Response to Surgery Be Assessed?
The currently accepted criteria for cure of acromegaly is a 
random or mean GH level of <5 mu/l or a nadir GH level of 
less than 2 mu/l during an OGTT and a serum IGF 1 level 
within the age-adjusted normal range [6]. The patient had 
an OGTT eight weeks after surgery as well as tests of anterior 
pituitary function. Nadir GH levels were 8.6 mu/l with a 
slightly raised IGF 1 level of 51 nmol/l, signifying partial 
resolution of acromegaly. Other anterior pituitary function 
doi:10.1371/journal.pmed.0040029.g002
Figure 2. MRI Studies of the Patient’s Pituitary Gland
MRI of the pituitary gland showing a non-enhancing lesion occupying 
the bulk of the pituitary fossa (yellow arrow). The remaining normal 
pituitary is pushed to the left, as is the pituitary stalk. The optic chiasm 
can be seen just superior to the pituitary gland (white arrow).
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Box 2. Protocol for Oral Glucose Tolerance 
and GH Suppression Test for Diagnosis of 
Acromegaly
•  Fast the patient from midnight.
•  Insert venous cannula prior to basal sample.
•  Administer oral 75 grams glucose at time 0 (just prior to basal 
blood sample) and collect blood samples for GH and glucose 
at 30-minute intervals up to 120 minutes.
•  Measure IGF 1 level with basal sample.PLoS Medicine  |  www.plosmedicine.org 0446
tests were normal. Repeat MRI scan showed no deﬁ  nite target 
for further surgical intervention.
She was then started on somatostatin analogue therapy to 
achieve better GH level control. This reduced mean GH levels 
to 2.9 mu/l and normalised IGF 1 levels to 32 nmol/l. After 
discussion with the patient, it was decided not to proceed 
with radiotherapy since the acromegaly was well controlled 
with medical therapy and due to the high probability of 
hypopituitarism associated with radiotherapy. She remains 
asymptomatic and is under regular endocrine follow-up.
DISCUSSION
Acromegaly is a rare condition with prevalence rates of 60 
per million population. The condition can cause signiﬁ  cant 
morbidity and mortality but may present with vague features; 
therefore a high index of clinical suspicion is warranted. 
The average delay in diagnosis after onset of the disease is 
about eight years. It can cause hypertension and disorders 
of glucose metabolism, which are increasing in prevalence, 
as well as soft tissue enlargement, which may take years 
to be noticed. The increasing use of imaging techniques 
has invented a new disorder—the incidentaloma. When 
incidentalomas are found in the pituitary, a thorough history 
and examination is required with relevant biochemical tests. 
The biochemical diagnostic criteria for acromegaly have 
changed over the past decade, bringing the GH diagnostic 
threshold to lower levels. The advent of better and more 
sensitive GH assays and better imaging have helped to 
diagnose more subtle forms of the disease, which would not 
have been picked up earlier, and may therefore hopefully 
reduce morbidity and mortality. Furthermore, newer 
treatment options, whilst expanding the therapeutic armour, 
also pose a challenge to the treating endocrinologist in 
deciding what best suits the patient.  
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Key Learning Points
•  Acromegaly is a rare but easily diagnosed condition that can 
cause signiﬁ  cant morbidity and mortality.
•  Increasing use of imaging has led to an increase of incidental 
ﬁ  ndings—the “incidentaloma”.
•  Symptoms of acromegaly may persist for many years before 
the diagnosis is made.
•  Newer modalities of GH assays and treatment have led to 
earlier diagnosis and may reduce symptoms and mortality.
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Table 2. Advantages and Limitations of Different Modalities of Treatment for Acromegaly
Advantages Disadvantages
Surgery Relieves symptoms and reduces mass effect. Reduces GH/IGF 1 
levels quickly (50%–90%).
Invasive. Hypopituitarism (10%–20%). Recurrence (5%–7%). 
Remission in only 50% of macro-adenomas.
Somatostatin analogues (octreotide, 
lanreotide)
Relieves symptoms. Reduces GH/IGF 1 levels within a few 
days (50%–80%). No hypopituitarism. Tumour shrinkage in 
20%–50% of cases.
2–6 weekly injections. Expensive. Gall stones (20%).
Dopamine agonists (cabergoline, 
bromocriptine)
Reduces GH/IGF 1 levels (20%). No hypopituitarism. Partial relief of symptoms. Gastro-intestinal side-effects. Does 
not shrink tumour or reduce mass effect in most cases (>80%).
GH receptor antagonists (pegvisomant) Relieves symptoms. Reduces IGF 1 levels (>90%). GH remains 
high. No hypopituitarism.
Daily injections. Expensive. Does not shrink tumour or reduce 
mass effect. Long-term safety unknown—tumour size may 
increase if used without concomitant somatostatin analogues.
Radiotherapy Tumour recurrence is very uncommon. Relieves symptoms and reduces GH/IGF 1 levels after months 
to years. Hypopituitarism quite common after 10 years. 
Possible long-term side effects of radiation.
doi:10.1371/journal.pmed.0040029.t002